IR@PKUHSC  > 北京大学基础医学院  > 病原生物学系
学科主题基础医学
Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients
Liang, Xieer1; Cheng, Jun3; Sun, Yongtao9; Chen, Xinyue4; Li, Tong6; Wang, Hao7; Jiang, Jianning10; Chen, Xiaoping2; Long, Hui11; Tang, Hong12; Yu, Yanyan8; Sheng, Jifang13; Chen, Shijun15; Niu, Junqi16; Ren, Hong17; Shi, Junping14; Dou, Xiaoguang18; Wan, Mobin19; Jiang, Jiaji23; Xie, Qing20; Shi, Guangfeng21; Ning, Qin24; Chen, Chengwei22; Tan, Deming25; Ma, Hong5; Sun, Jian1; Jia, Jidong5; Zhuang, Hui6; Hou, Jinlin1
关键词adefovir dipivoxil hepatitis B e antigen lamivudine optimization strategy virological response
刊名JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
2015-04-01
DOI10.1111/jgh.12835
30期:4页:748-755
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Gastroenterology & Hepatology
研究领域[WOS]Gastroenterology & Hepatology
关键词[WOS]ADEFOVIR DIPIVOXIL ; THERAPY ; TELBIVUDINE ; MANAGEMENT ; ENTECAVIR ; TENOFOVIR ; ROADMAP ; SAFETY
英文摘要

Background and AimData about the efficacy of de novo combination therapies, or optimization strategy by adding the other drug based on the virological response at week 24 of low genetic barrier antiviral agents is still limited. This study aimed to compare the efficacy at week 104 of lamivudine monotherapy (MONO), lamivudine plus adefovir dipivoxil (ADV) combination therapy (COMBO), and lamivudine optimization strategy (OPTIMIZE).

MethodsAdult patients without antiviral therapy within 6 months before screening with hepatitis B virus (HBV)-DNA10(5) copies/mL, alanine aminotransferase 1.3-10 times upper limit of normal and compensated hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) were randomized into three groups with 1:1:1 ratio. Patients in OPTIMIZE group started with lamivudine 100mg q.d., and ADV 10mg q.d. was added to suboptimal responders (HBV-DNA >1000 copies/mL at week 24) from week 30 to week 104, whereas patients with early virological response (HBV-DNA1000 copies/mL at week 24) continued MONO until week 104. For all the patients receiving MONO, ADV would be added if virological breakthrough was confirmed.

ResultsAt week 104, more patients in COMBO and OPTIMIZE groups achieved HBV-DNA<300 copies/mL (53.3% [64/120] and 48.3% [58/120]), with less lamivudine resistance (0.8% and 6.7%) compared with MONO group (HBV-DNA<300 copies/mL 34.8% [41/118], lamivudine resistance 58.5%). Patients under MONO with early virological response showed superior efficacy at week 104 (HBV-DNA<300 copies/mL 73.1% [38/52], HBeAg seroconversion 40.4% [21/52]). All regimens were well tolerated.

ConclusionCombination therapy of lamivudine plus ADV exhibited effective viral suppression and relatively low resistance in HBeAg-positive CHB patients. In lamivudine-treated patients with suboptimal virological response at week 24, promptly adding on ADV is necessary to prevent resistance development.

语种英语
WOS记录号WOS:000351403200023
项目编号2012ZX10002003
资助机构National Science and Technology Major Project of China
引用统计
被引频次:6[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
版本出版稿
条目标识符http://ir.bjmu.edu.cn/handle/400002259/66868
专题北京大学基础医学院_病原生物学系
北京大学基础医学院
北京大学第一临床医学院_感染疾病科
北京大学第二临床医学院_肝病科
作者单位1.Southern Med Univ, Nanfang Hosp, Guangdong Prov Key Lab Viral Hepatitis Res, State Key Lab Organ Failure Res,Dept Infect Dis, Guangzhou 510515, Guangdong, Peoples R China
2.Guangdong Gen Hosp, Dept Infect Dis, Guangzhou, Guangdong, Peoples R China
3.Capital Med Univ, Beijing Ditan Hosp, Beijing, Peoples R China
4.Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China
5.Capital Med Univ, Beijing Friendship Hosp, Liver Res Ctr, Beijing, Peoples R China
6.Peking Univ, Hlth Sci Ctr, Dept Microbiol, Beijing, Peoples R China
7.Peking Univ, Peoples Hosp, Hepatol Unit, Beijing, Peoples R China
8.Peking Univ, Hosp 1, Dept Infect Dis, Beijing 100871, Peoples R China
9.Fourth Mil Med Univ, Tangdu Hosp, Dept Infect Dis, Xian 710032, Peoples R China
10.First People Hosp Foshan, Dept Infect Dis, Foshan, Peoples R China
11.6th Peoples Hosp, Hangzhou, Zhejiang, Peoples R China
12.Jinan Infect Dis Hosp, Jinan, Peoples R China
13.Guangxi Med Univ, Affiliated Hosp 1, Dept Infect Dis, Nanning, Peoples R China
14.Sichuan Univ, West China Hosp, Ctr Infect Dis, Chengdu 610064, Peoples R China
15.Zhejiang Univ, Affiliated Hosp 1, Dept Infect Dis, Hangzhou 310003, Zhejiang, Peoples R China
16.Jilin Univ, Affiliated Hosp 1, Hepatol Unit, Changchun 130023, Peoples R China
17.Chongqing Med Univ, Affiliated Hosp 2, Dept Infect Dis, Chongqing, Peoples R China
18.China Med Univ, Shengjing Hosp, Dept Infect Dis, Shenyang 110001, Peoples R China
19.Second Mil Med Univ, Changhai Hosp, Dept Infect Dis, Shanghai, Peoples R China
20.Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Infect Dis, Shanghai 200030, Peoples R China
21.Fudan Univ, Huashan Hosp, Dept Infect Dis, Shanghai, Peoples R China
22.85th Peoples Liberat Army Hosp, Dept Infect Dis, Shanghai, Peoples R China
23.Fujian Med Univ, Affiliated Hosp 1, Ctr Liver, Fuzhou, Peoples R China
24.Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Infect Dis, Wuhan 430074, Peoples R China
25.Cent S Univ, Xiangya Hosp, Dept Infect Dis, Changsha, Hunan, Peoples R China
推荐引用方式
GB/T 7714
Liang, Xieer,Cheng, Jun,Sun, Yongtao,et al. Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients[J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY,2015,30(4):748-755.
APA Liang, Xieer.,Cheng, Jun.,Sun, Yongtao.,Chen, Xinyue.,Li, Tong.,...&Hou, Jinlin.(2015).Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients.JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY,30(4),748-755.
MLA Liang, Xieer,et al."Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients".JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 30.4(2015):748-755.
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
Randomized, three-ar(434KB)期刊论文出版稿开放获取CC BY-NC-SA浏览 请求全文
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Liang, Xieer]的文章
[Cheng, Jun]的文章
[Sun, Yongtao]的文章
百度学术
百度学术中相似的文章
[Liang, Xieer]的文章
[Cheng, Jun]的文章
[Sun, Yongtao]的文章
必应学术
必应学术中相似的文章
[Liang, Xieer]的文章
[Cheng, Jun]的文章
[Sun, Yongtao]的文章
相关权益政策
暂无数据
收藏/分享
文件名: Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients.pdf
格式: Adobe PDF
此文件暂不支持浏览
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。